[go: up one dir, main page]

WO2004080393A3 - Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central - Google Patents

Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central Download PDF

Info

Publication number
WO2004080393A3
WO2004080393A3 PCT/US2004/006782 US2004006782W WO2004080393A3 WO 2004080393 A3 WO2004080393 A3 WO 2004080393A3 US 2004006782 W US2004006782 W US 2004006782W WO 2004080393 A3 WO2004080393 A3 WO 2004080393A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
central nervous
cytokine inhibitory
selective cytokine
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/006782
Other languages
English (en)
Other versions
WO2004080393A2 (fr
Inventor
Peter H Schafer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ542408A priority Critical patent/NZ542408A/en
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to JP2006509174A priority patent/JP2006519875A/ja
Priority to CA002517845A priority patent/CA2517845A1/fr
Priority to CN2004800118192A priority patent/CN1780616B/zh
Priority to BRPI0408113-7A priority patent/BRPI0408113A/pt
Priority to AU2004220607A priority patent/AU2004220607B2/en
Priority to MXPA05009435A priority patent/MXPA05009435A/es
Priority to EP04717992A priority patent/EP1605935A4/fr
Publication of WO2004080393A2 publication Critical patent/WO2004080393A2/fr
Publication of WO2004080393A3 publication Critical patent/WO2004080393A3/fr
Priority to IL170710A priority patent/IL170710A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de traitement, de prévention et/ou de gestion de troubles du système nerveux central, notamment la malade de Parkinson, la maladie d'Alzheimer, une déficience cognitive légère, la maladie de Huntington, la sclérose latérale amyotrophique, la dépression et la déficience de mémoire à long terme, et des syndromes associés. L'invention concerne des méthodes spécifiques comprenant l'administration d'un médicament sélectif inhibitoire de cytokine, ou d'un sel, d'un solvate, d'un hydrate, d'un stéréoisomère, d'un clathrate, ou d'un promédicament pharmaceutiquement acceptable de celui-ci, seul ou combiné à un second principe actif. L'invention concerne également des compositions pharmaceutiques, des formes dosifiées unitaires, et des trousses appropriées à une utilisation dans les méthodes de l'invention.
PCT/US2004/006782 2003-03-06 2004-03-05 Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central Ceased WO2004080393A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP04717992A EP1605935A4 (fr) 2003-03-06 2004-03-05 Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central
JP2006509174A JP2006519875A (ja) 2003-03-06 2004-03-05 中枢神経系障害を治療するための選択的サイトカイン阻害剤
CA002517845A CA2517845A1 (fr) 2003-03-06 2004-03-05 Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central
CN2004800118192A CN1780616B (zh) 2003-03-06 2004-03-05 治疗中枢神经系统疾病的选择性细胞因子抑制药物
BRPI0408113-7A BRPI0408113A (pt) 2003-03-06 2004-03-05 métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica
NZ542408A NZ542408A (en) 2003-03-06 2004-03-05 Selective cytokine inhibitory drugs for treating disorders of the central nervous system
MXPA05009435A MXPA05009435A (es) 2003-03-06 2004-03-05 Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.
AU2004220607A AU2004220607B2 (en) 2003-03-06 2004-03-05 Selective cytokine inhibitory drugs for treating disorders of the central nervous system
IL170710A IL170710A0 (en) 2003-03-06 2005-09-06 Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45237403P 2003-03-06 2003-03-06
US60/452,374 2003-03-06

Publications (2)

Publication Number Publication Date
WO2004080393A2 WO2004080393A2 (fr) 2004-09-23
WO2004080393A3 true WO2004080393A3 (fr) 2004-12-02

Family

ID=32990646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006782 Ceased WO2004080393A2 (fr) 2003-03-06 2004-03-05 Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central

Country Status (12)

Country Link
EP (1) EP1605935A4 (fr)
JP (1) JP2006519875A (fr)
KR (1) KR100831545B1 (fr)
CN (1) CN1780616B (fr)
AU (1) AU2004220607B2 (fr)
BR (1) BRPI0408113A (fr)
CA (1) CA2517845A1 (fr)
IL (1) IL170710A0 (fr)
MX (1) MXPA05009435A (fr)
NZ (1) NZ542408A (fr)
WO (1) WO2004080393A2 (fr)
ZA (1) ZA200507322B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CA2789014C (fr) 2010-02-09 2019-01-15 Michela Gallagher Procedes et compositions pour ameliorer la fonction cognitive
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
WO2014144663A1 (fr) 2013-03-15 2014-09-18 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
JP6899043B2 (ja) 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド レベチラセタムの持続放出性医薬組成物
CN111542314B (zh) * 2017-10-18 2023-11-24 内在生物技术有限公司 神经退行性疾病的治疗剂
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
EP4241774A1 (fr) * 2020-11-04 2023-09-13 Gliacelltech Inc. Composition pour la prévention ou le traitement de maladies neuro-inflammatoires, comprenant de la chlorpromazine
CN119280228B (zh) * 2024-11-06 2025-09-19 桂林医学院附属医院 帕金森病神经保护作用药物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
AR003951A1 (es) * 1995-05-26 1998-09-30 Pfizer Formulacion farmaceutica sinergica para el tratamiento de la enfermedad de parkinson y composiciones para prepararla.
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
JP3568749B2 (ja) * 1996-12-17 2004-09-22 株式会社デンソー 半導体のドライエッチング方法
CA2295295A1 (fr) * 1997-07-31 1999-02-11 Celgene Corporation Acides alcanohydroxamiques substitues et procede permettant de reduire le niveau de tnf-.alpha.
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003222034A1 (en) * 2002-03-20 2003-10-08 Celgene Corporation (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US20050118715A1 (en) * 2002-04-12 2005-06-02 Hariri Robert J. Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders

Also Published As

Publication number Publication date
EP1605935A4 (fr) 2009-05-20
ZA200507322B (en) 2007-03-28
KR100831545B1 (ko) 2008-05-21
NZ542408A (en) 2009-03-31
CN1780616A (zh) 2006-05-31
AU2004220607A1 (en) 2004-09-23
KR20050109971A (ko) 2005-11-22
WO2004080393A2 (fr) 2004-09-23
EP1605935A2 (fr) 2005-12-21
JP2006519875A (ja) 2006-08-31
CA2517845A1 (fr) 2004-09-23
CN1780616B (zh) 2010-05-12
AU2004220607B2 (en) 2009-06-11
IL170710A0 (en) 2011-08-01
MXPA05009435A (es) 2005-11-23
BRPI0408113A (pt) 2006-03-01

Similar Documents

Publication Publication Date Title
WO2005043971A3 (fr) Procedes d'utilisations et compositions comprenant des medicaments selectifs inhibiteurs de la cytokine utilises dans le traitement, la modification et la gestion de la douleur
WO2005046318A3 (fr) Procedes d'utilisation et compositions comprenant des composes immunomodulatoires pour le traitement et la gestion de maladies et de troubles associe(e)s a l'amiante
WO2005097125A3 (fr) Methodes et compositions pour le traitement, la prevention ou la gestion des troubles du sommeil et des troubles du sommeil associes a une maladie
WO2004105702A3 (fr) Compositions pharmaceutiques expansibles et procedes de traitement d'un trouble donne
WO2008008474A3 (fr) Compositions et procédés de traitement des cas de douleur chronique
WO2000010551A3 (fr) Procedes d'utilisation d'inhibiteurs de recaptage de la dopamine et compositions contenant ces derniers
BRPI0315315B8 (fr)
CA2486101A1 (fr) Derives d'aminoindazole agissant comme inhibiteurs de kinase, methode d'obtention et compositions pharmaceutiques les renfermant
WO2004037207A3 (fr) Compositions contenant des medicaments selectifs inhibiteurs des cytokines, destinees a traiter, modifier et gerer la douleur, et leurs methodes d'utilisation
CA2534549A1 (fr) Derives de pteridine pour le traitement du choc septique et de maladies liees au tnf-.alpha.
WO2005002582A3 (fr) Composes actifs de trp-p8 et methodes de traitement therapeutique
WO2006058007A3 (fr) Procedes et compositions permettant d'utiliser des inhibiteurs jnk pour traiter et gerer une blessure du systeme nerveux central
WO2004034962A3 (fr) Methode d'utilisation de medicaments selectifs inhibiteurs des cytokines et compositions comprenant des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge de syndromes myelodysplasiques
WO2004080393A3 (fr) Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central
WO2004043378A3 (fr) Procedes et compositions utilisant des medicaments d'inhibition selective de cytokine pour traiter et maitriser des cancers et d'autres maladies
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
WO2005046593A3 (fr) Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
WO2005094218A3 (fr) Procedes d'utilisation et compositions comprenant des medicaments selectifs inhibiteurs de cytokine pour le traitement et la gestion de troubles du systeme nerveux central
WO2006124681A3 (fr) Systeme d'administration orale de medicaments et procedes d'utilisation
WO2005039497A3 (fr) Procedes et compositions a base de thalidomide pour le traitement des fibromyalgies
WO2004041190A3 (fr) Compositions comprenant des composes immunomodulateurs pour le traitement et la gestion d'une degeneration maculaire, ainsi que leurs methodes d'utilisation
WO2004037199A3 (fr) Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation
WO2005065372A3 (fr) Procedes et compositions faisant intervenir de la thalidomide pour le traitement et la prise en charge de troubles et maladies du systeme nerveux central
WO2005110085A3 (fr) Procedes d'utilisation et compositions comprenant des medicaments d'inhibition selective de cytokine, pour traiter et controler des syndromes myelodysplasiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2517845

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009435

Country of ref document: MX

Ref document number: 2006509174

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 170710

Country of ref document: IL

Ref document number: 1020057016598

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004220607

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/07322

Country of ref document: ZA

Ref document number: 200507322

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 542408

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004220607

Country of ref document: AU

Date of ref document: 20040305

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004717992

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004220607

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048118192

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057016598

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004717992

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408113

Country of ref document: BR